一名患有肝硬化和肝细胞癌的患者在接受索拉非尼治疗时出现急性肝炎。 - Suppr

Suppr

超能文献

Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.

作者信息

Llanos Lucia, Bellot Pablo, Zapater Pedro, Pérez-Mateo Miguel, Such Jose

出版信息

Am J Gastroenterol. 2009 Jan;104(1):257-8. doi: 10.1038/ajg.2008.41.

DOI:10.1038/ajg.2008.41

PMID:19098892

Abstract

摘要

相似文献

Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.

Am J Gastroenterol. 2009 Jan;104(1):257-8. doi: 10.1038/ajg.2008.41.

Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.

Transplantation. 2010 Jul 15;90(1):98-9. doi: 10.1097/TP.0b013e3181daac69.

Target therapy for hepatocellular carcinoma: is sorafenib for everybody?

J Clin Gastroenterol. 2009 May-Jun;43(5):389-90. doi: 10.1097/MCG.0b013e31819eb9a6.

Sorafenib-induced destructive thyroiditis.

Thyroid. 2010 Sep;20(9):1043-4. doi: 10.1089/thy.2010.0070.

[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].

Gastroenterol Hepatol. 2010 Dec;33(10):741-52. doi: 10.1016/j.gastrohep.2010.05.007. Epub 2010 Sep 18.

[Hepatocellular carcinoma - long-term treatable disease].

Klin Onkol. 2012;25(4):287-9.

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525.

Sorafenib in advanced hepatocellular carcinoma.

N Engl J Med. 2008 Dec 4;359(23):2497-8; author reply 2498-9. doi: 10.1056/NEJMc081780.

Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.

Oncologist. 2009 Jan;14(1):67-9. doi: 10.1634/theoncologist.2008-0281. Epub 2009 Jan 15.

All that glitters: sorafenib.

Intern Med. 2011;50(7):797. doi: 10.2169/internalmedicine.50.4858. Epub 2011 Apr 1.

引用本文的文献

Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats.

Molecules. 2017 Jun 22;22(7):1034. doi: 10.3390/molecules22071034.

Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?

Oncotarget. 2016 Oct 11;7(41):67650-67660. doi: 10.18632/oncotarget.11767.

New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials.

Front Pharmacol. 2016 Jan 18;6:300. doi: 10.3389/fphar.2015.00300. eCollection 2015.

Sorafenib-induced liver failure: a case report and review of the literature.

Case Reports Hepatol. 2011;2011:941395. doi: 10.1155/2011/941395. Epub 2011 Dec 12.

Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.

J Neuroimmune Pharmacol. 2014 Mar;9(2):69-79. doi: 10.1007/s11481-013-9484-2. Epub 2013 Jun 25.

Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Drug Saf. 2013 Jul;36(7):491-503. doi: 10.1007/s40264-013-0048-4.

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.

BMC Cancer. 2012 Dec 11;12:590. doi: 10.1186/1471-2407-12-590.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验